CASI Pharmaceuticals Inc (CASI)

NASDAQ
2.6900
+0.0700(+2.67%)
After Hours
2.6800
-0.0100(-0.3717%)
- Real-time Data
  • Volume:
    74,371
  • Day's Range:
    2.5701 - 2.7001
  • 52 wk Range:
    2.2400 - 12.5000

CASI Overview

Prev. Close
2.62
Day's Range
2.5701-2.7001
Revenue
34.9M
Open
2.62
52 wk Range
2.24-12.5
EPS
-2.32
Volume
74,371
Market Cap
36.6M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
214,003
P/E Ratio
-1.59
Beta
0.635
1-Year Change
-78.48%
Shares Outstanding
13,606,130
Next Earnings Date
Nov 15, 2022
What is your sentiment on Casi Pharma?
or
Market is currently closed. Voting is open during market hours.

CASI Pharmaceuticals Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade
  • CASI Pharma Tops Q1 EPS by 3c
    • ByInvesting.com-

    CASI Pharma (CASI) reported Q1 EPS of ($0.06), $0.03 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $9 million versus the consensus estimate of...

  • Baidu Falls as SEC Action Raises Delisting Fears
    • ByInvesting.com-

    By Dhirendra Tripathi Investing.com – Baidu (NASDAQ:BIDU) stock traded 3.5% weaker in premarket Thursday after the U.S. securities regulator added its name to the list of...

CASI Pharmaceuticals Inc Analysis

CASI Pharmaceuticals Inc Company Profile

CASI Pharmaceuticals Inc Company Profile

Employees
176

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States and throughout the world. It is also focused on acquiring, developing, and commercializing products that augment its hematology-oncology therapeutic focus as well as other areas of unmet medical need. The Company’s operations in China are conducted primarily through its subsidiaries, which include CASI Pharmaceuticals (China) Co., Ltd. (CASI China), which is wholly owned and is located in Beijing, China, and CASI Pharmaceuticals (Wuxi) Co., Ltd. (CASI Wuxi), which is located in Wuxi, China. Its commercial product, EVOMELA, is developed for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The Company’s other core hematology/oncology assets in its pipeline include CNCT19, BI-1206, CB-5339 and CID-103.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralSellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong SellStrong SellStrong Sell
SummaryStrong BuyBuyStrong SellStrong SellStrong Sell
  • The next GME or AMC?
    0
    • I wouldn't mind it dropped 85% and lower than that...
      0
      • And is voted 50/50
        0
        • since may 23 it is up over 88.20% from 3.7800 go figure 🤔
          0
          • the price is wrong, it is 0.3443 not 3.4430
            0
            • Stay away from this stock! from a current shareholder
              0
              • Time to think for buying…
                0
                • this is not going well..:(
                  0
                  • CEO purchased 3.3 million shares two days ago. Something is up....
                    0
                    • https://www.americanbankingnews.com/2021/03/04/casi-pharmaceuticals-inc-nasdaqcasi-expected-to-post-quarterly-sales-of-4-45-million.html
                      0